# Ai Genomics Market

> AI in Genomics Market Research Report: Size, Share, Trend Analysis By Applications (Drug Discovery, Genomic Data Analysis, Personalized Medicine, Agrigenomics, Diagnostics), By Technology (Machine Learning, Deep Learning, Natural Language Processing, Computer Vision), By Deployment Type (Cloud-Based, On-Premises), By End Users (Pharmaceutical Companies, Biotechnology Firms, Research Institutions, Healthcare Providers), By Solution Type (Software, Services) and By Regional - Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 17.88%
- **2024:** $ 14.22 Billion
- **2025:** $ 16.76 Billion
- **2035:** $ 86.85 Billion
- **Key Players:** Companies such as Illumina (US), Thermo Fisher Scientific (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), GRAIL (US), Freenome (US), Zymergen (US), BenevolentAI (GB), Genomatix (DE) are some of the major participants in the global market.

**Report ID:** MRFR/LS/29504-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 14, 2026

**URL:** https://www.marketresearchfuture.com/reports/ai-genomics-market-31278

---

## Market Summary

## **AI in Genomics Market Overview:**

As per MRFR analysis, the AI in Genomics Market Size was estimated at 14.22 (USD Billion) in 2024. The AI in Genomics Market Industry is expected to grow from 16.76 (USD Billion) in 2025 to 73.68 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 17.88% during the forecast period (2025 - 2034).

## **Key AI in Genomics Market Trends Highlighted**

The AI in Genomics Market is witnessing significant growth fueled by advancements in artificial intelligence and its applications in genomic research and personalized medicine. Key market drivers include the increasing demand for precision medicine, where tailored treatments are provided based on an individual's genetic makeup. The ability of AI to analyze vast amounts of genomic data efficiently and accurately enhances drug discovery and diagnostic processes, thereby reducing time to market for new therapies. The continual improvement in machine learning algorithms and data analytics further supports the integration of AI in genomics, making it an indispensable tool for researchers and healthcare providers.

Opportunities in the AI genomics arena are abundant, particularly in the realms of early disease detection and management, drug development, and agricultural genomics. The potential to harness AI-driven insights for genetic modifications and improved crop yields offers promising avenues for innovation. Moreover, the growing trend towards population genomics and biobanking provides a fertile ground for developing AI applications that can analyze genetic correlations across diverse populations. Collaborations between technology firms and research institutions also present opportunities for advancing AI solutions tailored to genomic needs.

Recent trends highlight an increase in investments focused on integrating AI technologies in genomic research, with firms striving to consolidate their positions through mergers and acquisitions. The advent of cloud-based genomic platforms is reshaping data accessibility, allowing for collaborative research and accelerating findings in genomic studies. Furthermore, ethical considerations surrounding gene editing and data privacy are gaining attention, prompting discussions on regulatory frameworks that would support responsible AI use in genomics without stifling innovation. These evolving dynamics underline the transformative potential of AI in genomics, driving a shift towards more personalized, efficient, and informed healthcare solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **AI in Genomics Market Drivers**

### Advancements in AI **Technology**

The rapid advancements in artificial intelligence technology are significantly driving the AI in Genomics Market Industry forward. The integration of machine learning algorithms and deep learning techniques has enabled researchers to interpret and analyze vast amounts of genomic data with unprecedented accuracy and efficiency. This evolution in computational power allows for the identification of genetic variants, patterns, and anomalies that were previously undetectable using traditional genomic analysis methods.

As the cost of sequencing decreases and the speed of data processing increases, AI tools can leverage these large datasets to enhance personalized medicine approaches. This means tailored treatments can become a reality, targeting specific genetic profiles, thus improving patient outcomes significantly. Furthermore, AI's ability to continuously learn and adapt contributes to the development of predictive models that can forecast disease susceptibility and treatment responses, revolutionizing the way healthcare is delivered.

The combination of AI and genomics is set to reshape research methodologies, clinical trials, and therapeutic strategies, making this integration a core driver of the AI in Genomics Market. As a result, investments in AI technologies and collaborations among tech companies, research institutions, and healthcare providers are on the rise, ensuring that this driver will continue to have a substantial impact on market growth in the foreseeable future.

### **Growing Demand for Genomic Medicine**

The increasing demand for genomic medicine is a vital driver in the AI in Genomics Market Industry. As awareness about precision medicine grows, patients and healthcare providers are more inclined to seek genomic insights for effective treatment plans. The shift towards personalized healthcare requires advanced genetic understanding, which is only achievable through AI-powered genomic analysis. This trend is propelling investments and innovations aimed at enhancing patient care through tailored therapeutics.

### **Mergers and Partnerships in the Biotechnology Sector**

Strategic mergers and partnerships within the biotechnology sector are strengthening the AI in Genomics Market Industry. These collaborations between established biotech firms and AI technology companies facilitate the exchange of expertise and resources, which enhances the development of genomics-based solutions. By pooling their capabilities, these entities can accelerate research and product development, ultimately pushing market growth.

## **AI in Genomics Market Segment Insights:**

### **AI in Genomics Market Application Insights   **

The AI in Genomics Market is experiencing significant growth, particularly in its Application segment, which is projected to reach substantial valuations by 2032. This growth is largely fueled by advancements in data analytics, an increased emphasis on personalized healthcare, and the need for efficient drug discovery processes. Within the Application segment, the demand for innovative solutions is diversifying into several key sub-segments: Drug Discovery, Genomic Data Analysis, Personalized Medicine, Agrigenomics, and Diagnostics.

Drug Discovery is emerging as a critical area within the AI in Genomics Market, currently valued at 3.5 USD Billion in 2023, it is estimated to escalate to 15.75 USD Billion by 2032.

The integration of AI technologies in drug discovery is streamlining research and development processes, reducing time and costs associated with bringing new drugs to market. Following closely is Genomic Data Analysis, valued at 2.2 USD Billion in 2023 and anticipated to grow to 9.9 USD Billion by 2032. This sub-segment is surged by the increasing availability of genomic data, where AI is being utilized to enhance the extraction of insights from complex datasets, allowing for better interpretation and utilization of genetic information.

Personalized Medicine is another pivotal sub-segment, starting at 2.3 USD Billion in 2023 and projected to reach 10.5 USD Billion in 2032.

The increasing focus on tailoring treatment plans to individual genetic profiles is driving this segment, making use of AI algorithms to analyze patient data to provide personalized therapeutic options. Agrigenomics, crucial for improving food security and agricultural efficiency, is projected to grow from 1.3 USD Billion in 2023 to 6.0 USD Billion in 2032, as AI helps in the genetic modification and yield improvement of crops and livestock.

Lastly, Diagnostics, which focuses on precise disease detection, is valued at 0.93 USD Billion in 2023 and expected to increase to 3.85 USD Billion by 2032, with AI facilitating the interpretation of genomic data to identify abnormalities swiftly.

The interplay of these sub-segments reflects the overall market growth trends, revealing a significant opportunity for expansion in the AI in Genomics Market as the healthcare landscape evolves. Market growth is driven by technological advancements, increasing investments in genomics, rising demand for precision and personalized healthcare, and a greater understanding of genomic data. However, challenges such as data privacy concerns and the need for regulatory approvals may impact the pace of growth. Overall, the AI in Genomics Market segmentation in Applications illustrates a dynamic landscape enriched with opportunities for innovative developments across various industries including healthcare, agriculture, and diagnostics.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **AI in Genomics Market Technology Insights   **

Among the various sub-segments, Machine Learning is emerging as a critical driver, primarily facilitating Drug Discovery, which is forecasted to grow from 3.5 USD Billion in 2023 to 15.75 USD Billion by 2032. Natural Language Processing (NLP) is also gaining traction, especially in genomics data interpretation and personalized medicine, which is expected to increase in value from 2.3 USD Billion in 2023 to 10.5 USD Billion by 2032. Deep Learning technologies are set to enhance Genomic Data Analysis, moving from 2.2 USD Billion in 2023 to 9.9 USD Billion a decade later.

Additionally, Computer Vision applications in Agrigenomics, currently valued at 1.3 USD Billion in 2023, are projected to reach 6.0 USD Billion by 2032. As the AI in Genomics Market continues to evolve, trends in advanced analytics, precision health, and automation present both challenges and opportunities for stakeholders, influencing the overall AI in Genomics Market Statistics and industry dynamics.

### **AI in Genomics Market Deployment Type Insights   **

The Deployment Type segment of the AI in Genomics Market is experiencing significant growth as the market is projected to reach a valuation of 45.0 USD Billion by 2032, up from 10.23 USD Billion in 2023. This growth is driven by an expected CAGR of 17.88% from 2025 to 2034. The Cloud-Based deployment is expected to lead the market due to its scalability, cost-effectiveness, and ability to handle large datasets, while On-Premises solutions are preferred by organizations with stringent data security and compliance requirements.

Among the various sub-segments, Drug Discovery is anticipated to showcase remarkable growth, with market values ascending from 3.5 USD Billion in 2023 to 15.75 USD Billion by 2032.

### **AI in Genomics Market End User Insights   **

The AI in Genomics Market is poised for substantial growth, with its overall market revenue expected to reach 45.0 USD Billion by 2032, up from 10.23 USD Billion in 2023, indicating a marked increase driven by various end user segments. Key players in this market include Pharmaceutical Companies, Biotechnology Firms, Research Institutions, and Healthcare Providers, all leveraging AI technologies to enhance their genomic capabilities.

The Drug Discovery sub-segment stands out, projected to grow from 3.5 USD Billion in 2023 to 15.75 USD Billion in 2032, as companies seek innovative ways to expedite the development of new therapies.Overall, the market dynamics exhibit a robust trajectory for the AI in Genomics Market, accentuated by the transformative potential of AI in genomic applications.

### **AI in Genomics Market Solution Type Insights   **

The AI in Genomics Market is projected to experience substantial growth driven by its diverse solution types, including software and services. As the market is expected to be valued at 10.23 USD Billion in 2023 and grow to approximately 45.0 USD Billion by 2032, this indicates a significant opportunity within the realm of genomic data analysis and application. Specifically, the software segment, which encompasses critical applications for drug discovery, genomic data analysis, personalized medicine, agrigenomics, and diagnostics, shows promising potential.

Furthermore, services associated with these solutions are set to expand, providing insights and expert assistance in navigating complex genomic landscapes.

### **AI in Genomics Market Regional Insights**

North America is poised to dominate the market, mainly driven by high investments in genomic research and advanced healthcare infrastructure. In contrast, Europe is also showing substantial potential, with innovations in personalized medicine leading to a rise in its market share. The APAC region is emerging rapidly, buoyed by an increase in healthcare spending and technological advancements in genomics. South America and MEA, while currently smaller sub-regions in the AI in Genomics Market revenue, are witnessing an increased focus on genetic research and diagnostics, facilitating growth opportunities ahead.

Within these regions, sub-segments such as Drug Discovery, projected to be valued at 15.75 USD Billion by 2032, and Genomic Data Analysis, expected to reach 9.9 USD Billion by 2032, are set to be significant contributors to the overall market expansion. Personalized Medicine is another critical area, with a growth forecast to reach 10.5 USD Billion by 2032, reflecting the intensifying trend toward individualized healthcare solutions.

The continued evolution of diagnostic technologies and their applications in Agrigenomics, valued at 6.0 USD Billion by 2032, also represents an important segment within the AI in Genomics Market segmentation, revealing the comprehensive nature of this industry amidst various regional dynamics and emerging trends.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **AI in Genomics Market Key Players And Competitive Insights:**

The AI in Genomics Market is evolving rapidly, driven by advancements in artificial intelligence technologies and the increasing volume of genomic data. This market encompasses a variety of applications ranging from drug discovery, personalized medicine, genetic testing, and data analysis, resulting in a competitive landscape that features numerous players vying for technological superiority and market share. Key factors influencing the dynamics of this market include innovation in machine learning algorithms, enhanced computational power, regulatory challenges, and the increasing awareness of genomics in healthcare.

Companies in this field are exploring collaborative efforts, partnerships, and mergers and acquisitions to enhance their product offerings and expand their reach, resulting in a constant reshuffling of competitive positioning.

DnaNudge stands out in the AI in Genomics Market with its unique approach to integrating genomics and consumer health. The company's strength lies in its proprietary technology that enables real-time genetic testing and personalized dietary recommendations, allowing users to make informed lifestyle choices based on their genetic profiles. DnaNudge’s innovative platform leverages artificial intelligence to interpret complex genomic data, resulting in actionable insights that resonate with health-conscious consumers and healthcare professionals alike.

The company is well-positioned in the market due to its user-friendly applications and the rising trend of personalized medicine. DnaNudge's focus on consumer engagement and empowerment through genetic insights strengthens its competitive advantage, making it a notable player in the genomic landscape.BioSymetrics operates within the AI in Genomics Market, specializing in AI-driven solutions for understanding complex biological data. This company focuses on combining clinical, genomic, and biometric data to develop predictive models that can enhance drug discovery processes and facilitate targeted therapeutic strategies. 

BioSymetrics has established a unique data architecture that allows for the integration and analysis of multi-modal data, which is essential in the personalized medicine arena. The strength of BioSymetrics lies in its cutting-edge algorithms and analytical capabilities that streamline the translation of genomic data into clinical applications. The company’s commitment to innovation and a deep focus on machine learning techniques empower it to deliver valuable insights to researchers and healthcare providers, placing BioSymetrics as a competitive entity in the ever-growing AI genomics space.

**Key Companies in the AI in Genomics Market Include:**

- DnaNudge
- **[BioSymetrics](https://www.biosymetrics.com/)**
- Invitae Corporation
- BenevolentAI
- BGI Genomics
- Zymo Research
- Nference
- Deep Genomics
- Illumina
- WuXi AppTec
- Genomatix GmbH
- Thermo Fisher Scientific
- Fabric Genomics
- Ginkgo BioWorks

## Ai Genomics Market Industry Developments

- **Q2 2024: Illumina and NVIDIA Collaborate to Accelerate AI Genomics Analysis** Illumina announced a partnership with NVIDIA to integrate NVIDIA's AI computing platform into Illumina's genomics analysis workflows, aiming to speed up and scale genomic data interpretation for research and clinical applications.
- **Q2 2024: Fabric Genomics Raises $30 Million in Series C Funding to Advance AI-Driven Genomic Interpretation** Fabric Genomics secured $30 million in Series C funding to expand its AI-powered genomic interpretation platform, supporting clinical diagnostics and precision medicine initiatives.
- **Q2 2024: Tempus Announces Acquisition of AI Genomics Startup Pangea Biomed** Tempus, a leader in AI-driven precision medicine, acquired Pangea Biomed, an AI genomics startup, to enhance its oncology and rare disease genomics capabilities.
- **Q3 2024: Oxford Nanopore Technologies and Microsoft Partner to Develop AI Genomics Tools** Oxford Nanopore Technologies entered a strategic partnership with Microsoft to co-develop AI-powered tools for real-time genomic data analysis, targeting healthcare and research markets.
- **Q3 2024: Grail Launches New AI-Enabled Genomic Cancer Screening Test** Grail announced the commercial launch of a new AI-enabled genomic test designed to detect multiple types of cancer from a single blood draw, leveraging advanced machine learning algorithms.
- **Q3 2024: SOPHiA GENETICS Expands AI Genomics Platform to Asia Through Partnership with BGI** SOPHiA GENETICS formed a partnership with BGI to expand its AI-powered genomics analytics platform into Asian markets, aiming to accelerate adoption in clinical and research settings.
- **Q4 2024: Deep Genomics Raises $100 Million Series D to Advance AI Drug Discovery Platform** Deep Genomics closed a $100 million Series D funding round to further develop its AI-driven platform for genomic drug discovery and expand its therapeutic pipeline.
- **Q4 2024: PathAI Receives FDA Clearance for AI Genomics Companion Diagnostic** PathAI announced FDA clearance for its AI-powered genomics companion diagnostic, enabling more precise patient selection for targeted cancer therapies.
- **Q1 2025: Celsius Therapeutics Raises $75 Million Series B to Scale AI Genomics Platform** Celsius Therapeutics raised $75 million in Series B funding to scale its AI-driven genomics platform focused on autoimmune disease and oncology research.
- **Q1 2025: DNAnexus Launches AI-Enhanced Genomics Data Platform for Biopharma** DNAnexus launched a new AI-enhanced genomics data platform designed to support biopharmaceutical companies in large-scale genomic data analysis and drug development.
- **Q2 2025: 23andMe Appoints New Chief AI Officer to Lead Genomics Innovation** 23andMe appointed a Chief AI Officer to spearhead the company's efforts in integrating artificial intelligence into its consumer genomics and health research initiatives.
- **Q2 2025: Helix Opens New AI Genomics Research Facility in San Diego** Helix announced the opening of a new research facility in San Diego dedicated to advancing AI-powered genomics research and accelerating the development of precision medicine solutions.

## **AI in Genomics Market Segmentation Insights**

### **AI in Genomics Market Application Outlook**

- Drug Discovery
- Genomic Data Analysis
- Personalized Medicine
- Agrigenomics
- Diagnostics

### **AI in Genomics Market Technology Outlook**

- Machine Learning
- Deep Learning
- Natural Language Processing
- Computer Vision

### **AI in Genomics Market Deployment Type Outlook**

- Cloud-Based
- On-Premises

### **AI in Genomics Market End User Outlook**

- Pharmaceutical Companies
- Biotechnology Firms
- Research Institutions
- Healthcare Providers

### **AI in Genomics Market Solution Type Outlook**

- Software
- Services

### **AI in Genomics Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Demand for Personalized Medicine

The AI in Genomics Market is significantly influenced by the rising demand for personalized medicine. As healthcare shifts towards tailored treatment plans, genomic data plays a crucial role in understanding individual patient profiles. This trend is evident in the increasing number of clinical trials focusing on genomics-based therapies. According to recent estimates, the personalized medicine market is expected to reach USD 2 trillion by 2030, with a substantial portion attributed to genomic innovations.
 
AI technologies facilitate the analysis of genomic data, enabling healthcare providers to develop customized treatment strategies. Consequently, the integration of AI in genomics is becoming essential for pharmaceutical companies aiming to enhance drug development processes and improve patient outcomes.

### Increased Investment in Genomic Research

The AI in Genomics Market is benefiting from increased investment in genomic research. Governments and private entities are allocating substantial funds to explore the potential of genomics in various fields, including agriculture, healthcare, and biotechnology. For instance, funding for genomic research initiatives has seen a notable rise, with investments exceeding USD 10 billion in recent years.
 
This influx of capital is fostering innovation and collaboration among researchers, leading to the development of novel AI applications in genomics. As a result, the market is likely to expand as new technologies emerge, enabling more efficient data analysis and interpretation. The synergy between AI and genomics is expected to unlock new avenues for research and development, further solidifying the industry's growth trajectory.

### Advancements in Machine Learning Algorithms

The AI in Genomics Market is experiencing a surge due to advancements in machine learning algorithms. These algorithms enhance the ability to analyze complex genomic data, leading to more accurate predictions and insights. For instance, the integration of deep learning techniques has shown promise in identifying genetic variants associated with diseases. As a result, the market is projected to grow at a compound annual growth rate of approximately 30% over the next five years.
 
This growth is driven by the increasing demand for precision medicine, which relies heavily on genomic data analysis. Furthermore, the ability of these algorithms to process vast datasets efficiently is likely to attract investments from both public and private sectors, further propelling the AI in Genomics Market.

### Emergence of Collaborative Research Initiatives

The AI in Genomics Market is being shaped by the emergence of collaborative research initiatives. Partnerships between academic institutions, healthcare organizations, and technology companies are fostering innovation in genomics. These collaborations aim to leverage AI technologies to enhance data sharing and analysis capabilities. For example, initiatives that combine genomic data with clinical information are paving the way for breakthroughs in understanding complex diseases.
 
The collaborative approach is likely to accelerate the development of AI-driven solutions in genomics, as diverse expertise converges to tackle pressing challenges. This trend not only enhances the quality of research but also promotes the translation of findings into clinical applications, thereby driving the growth of the AI in Genomics Market.

### Growing Adoption of Genomic Sequencing Technologies

The AI in Genomics Market is witnessing a growing adoption of genomic sequencing technologies. As sequencing costs continue to decline, more institutions are integrating these technologies into their research and clinical practices. The market for genomic sequencing is projected to reach USD 25 billion by 2026, driven by advancements in sequencing methods and the increasing availability of genomic data.
 
AI plays a pivotal role in analyzing the vast amounts of data generated by sequencing, enabling researchers to derive meaningful insights. This trend is likely to enhance the efficiency of genomic studies and accelerate the pace of discoveries in personalized medicine and disease prevention. The collaboration between AI and genomic sequencing is expected to redefine the landscape of genomics research.

## Future Outlook

The AI in Genomics Market size is projected to reach USD 86.85 Billion by 2035, growing at a CAGR of 17.88%, driven by advancements in data analytics, personalized medicine, and genomic research.

**New opportunities:**

- Development of AI-driven genomic data analysis platforms
- 
- Integration of AI in precision medicine workflows
- Creation of AI-based predictive models for genetic disorders

By 2035, the AI in Genomics Market is expected to be a pivotal sector in healthcare innovation.

## Segment Insights

### By Application: Drug Discovery (Largest) vs. Personalized Medicine (Fastest-Growing)

In the AI in Genomics market, the application segments are characterized by distinct roles across the industry. Drug Discovery currently holds the largest market share, driven by significant investments in AI technologies, which streamline the drug development process, thereby accelerating the time-to-market. Conversely, Personalized Medicine is gaining momentum as it leverages AI to tailor treatments based on genomic data, reflecting a growing consumer demand for customized healthcare solutions.

Drug Discovery (Dominant) vs. Personalized Medicine (Emerging)

Drug Discovery remains dominant in the AI in Genomics market due to its established methodologies and extensive funding focused on enhancing research and development. AI technologies are revolutionizing this space by predicting the efficacy and safety of drugs early in the process. On the other hand, Personalized Medicine is an emerging sector characterized by its innovative approach to tailoring health solutions based on individual genomic information. Fueled by advancements in AI, it significantly improves patient outcomes and aligns with the increasing shift toward tailored healthcare, making it an attractive investment and research area.

### By Technology: Machine Learning (Largest) vs. Deep Learning (Fastest-Growing)

In the AI in Genomics Market, the distribution among the technology segments reveals that Machine Learning holds the largest share, attributed to its established foundation and broad application in genomic data analysis. It allows researchers to uncover complex patterns in large datasets quickly. [Deep Learning](https://www.marketresearchfuture.com/reports/deep-learning-market-6058), while a more recent innovation, is gaining traction due to its superior ability to handle unstructured data and generate insights that were previously unattainable. This segment is rapidly expanding as algorithms improve and computational power increases, making it a central player in next-gen genomics capabilities. The growth trends in these technologies are driven by advancements in computational capabilities and an increasing volume of genetic data. The integration of these technologies enables personalized medicine and advanced genome editing, enhancing the drug discovery process. As investments in genomics research continue to surge, especially from biotechnology firms, the demand for both Machine Learning and Deep Learning applications will only increase. Furthermore, the symbiotic relationship between these technologies and innovations in data collection techniques is poised to accelerate their adoption further.

Technology: Machine Learning (Dominant) vs. Deep Learning (Emerging)

Machine Learning has established itself as a dominant force in the market share, facilitating a plethora of applications from predictive modeling to genomic mapping. Its framework allows for efficient handling of large-scale genomic data, which correlates with existing biological knowledge to predict outcomes. Conversely, Deep Learning is recognized as an emerging technology, representing a shift towards advanced neural network architectures that are capable of identifying intricate patterns within genomic sequences. This growing segment is characterized by its capability to improve accuracy in gene expression analysis and disease prediction. As research in genome and phenotype correlations continues to evolve, both segments will play crucial roles in shaping treatment pathways and patient outcomes.

### By Deployment Type: Cloud-Based (Largest) vs. On-Premises (Fastest-Growing)

In the AI in Genomics Market, the deployment type segment is prominently shaped by cloud-based solutions, which have solidified their position as the largest segment due to their scalability, accessibility, and cost-effectiveness. These solutions enable researchers and healthcare professionals to leverage vast computing resources without the upfront costs associated with physical hardware. On-premises deployment, while smaller in market share, is gaining traction among organizations with stringent data security and compliance requirements, as they prefer to maintain control over sensitive genomic data within their own infrastructure.

Deployment Type: Cloud-Based (Dominant) vs. On-Premises (Emerging)

Cloud-based deployment in the market share is characterized by its ability to provide flexible, scalable resources that cater to the dynamic computing needs of genomic research and analysis. This deployment method allows users to access powerful AI tools and large datasets from anywhere, facilitating collaboration among researchers across the globe. On the other hand, on-premises solutions are emerging as a viable choice for institutions that prioritize data security and privacy, as these setups offer greater control over data handling and regulatory compliance. These organizations are increasingly investing in on-premises infrastructure to accommodate specific use cases that require sensitive genomic data to remain within secure local environments, thus driving rapid growth in this segment.

### By End User: Pharmaceutical Companies (Largest) vs. Healthcare Providers (Fastest-Growing)

In the AI in Genomics Market, Pharmaceutical Companies account for the largest share, leveraging AI technologies to improve drug discovery and development processes. They utilize genomics data to tailor treatments, resulting in more efficient and effective therapies. Meanwhile, Research Institutions and Biotechnology Firms play significant roles, but their shares are comparatively smaller, indicating a concentrated dominance by pharmaceutical players in this sector. Healthcare Providers, emerging as the fastest-growing segment, are increasingly adopting AI in genomics to enhance patient care, personalize treatments, and streamline operational efficiencies. The advancement in genomics and the integration of AI have also fostered collaborations between healthcare providers and genomic researchers, creating an ecosystem driven by innovation and patient-centric approaches.

Healthcare Providers (Dominant) vs. Biotechnology Firms (Emerging)

Healthcare Providers have established a dominant position in the market share as they increasingly adopt advanced genomic technologies to enhance patient outcomes. Their commitment to personalized medicine and efficient care delivery is driving innovative use cases for AI, such as predictive analytics and genomic data interpretation. Conversely, Biotechnology Firms represent an emerging force, leveraging AI to expedite drug discovery and development processes. While they may not hold the same market share as healthcare providers, their agile operations and focus on novel therapeutics position them as key players in the market, with potential for significant growth as collaboration between technology and biology continues to evolve.

### By Solution Type: Software (Largest) vs. Services (Fastest-Growing)

In the AI in Genomics market, the solution type segment is predominantly led by software, which holds a significant share due to its essential role in data analysis and interpretation for genomic insights. Software solutions offer a range of functionalities, from machine learning algorithms to visualization tools, making them invaluable to genomics researchers and healthcare providers alike. Services represent the fastest-growing segment, as organizations seek expert consulting and implementation support to effectively integrate AI technologies into their genomic workflows.

Solution Type: Software (Dominant) vs. Services (Emerging)

Software solutions in the market share are recognized as the dominant force, providing essential tools for data management and analysis. Leading software offerings include platforms that leverage advanced algorithms to facilitate genetic data analysis, predictive modeling, and personalized medicine strategies. Conversely, the services segment is emerging rapidly due to the increasing demand for support services, including implementation, training, and technical assistance, as organizations navigate the complexities of AI integration. This growth is driven by the need for specialized knowledge and expertise to enhance the capabilities of existing genomic systems and maximize the benefits of AI technologies.

## Regional Market Share Analysis

North America leads in the AI in Genomics Market Size, accounting for over 45.01% of the global revenue in 2024, mainly driven by high investments in genomic research and advanced healthcare infrastructure. In contrast, Europe AI in Genomics Market was valued at USD 4.27 billion in 2024, making it the second-largest regional market with a 30% share, with innovations in personalized medicine leading to a rise in its market share.

The APAC region is emerging rapidly, buoyed by an increase in healthcare spending and technological advancements in genomics. South America and MEA, while currently smaller sub-regions in the AI in Genomics Market revenue, are witnessing an increased focus on genetic research and diagnostics, facilitating growth opportunities ahead.

Within these regions, sub-segments such as Drug Discovery, projected to be valued at 15.75 USD Billion by 2032, and Genomic Data Analysis, expected to reach 9.9 USD Billion by 2032, are set to be significant contributors to the overall market expansion. Personalized Medicine is another critical area, with a growth forecast to reach 10.5 USD Billion by 2032, reflecting the intensifying trend toward individualized healthcare solutions.

The continued evolution of diagnostic technologies and their applications in Agrigenomics, valued at 6.0 USD Billion by 2032, also represents an important segment within the AI in Genomics Market segmentation, revealing the comprehensive nature of this industry amidst various regional dynamics and emerging trends.

## Competitive Benchmarking

The AI in Genomics Market is evolving rapidly, driven by advancements in artificial intelligence technologies and the increasing volume of genomic data. This market encompasses a variety of applications ranging from drug discovery, personalized medicine, genetic testing, and data analysis, resulting in a competitive landscape that features numerous players vying for technological superiority and market share.
 
Key factors influencing the dynamics of this market include innovation in machine learning algorithms, enhanced computational power, regulatory challenges, and the increasing awareness of genomics in healthcare.Companies in this field are exploring collaborative efforts, partnerships, and mergers and acquisitions to enhance their product offerings and expand their reach, resulting in a constant reshuffling of competitive positioning.
 
DnaNudge stands out in the AI in Genomics Market with its unique approach to integrating genomics and consumer health. The company's strength lies in its proprietary technology that enables real-time genetic testing and personalized dietary recommendations, allowing users to make informed lifestyle choices based on their genetic profiles. DnaNudge’s innovative platform leverages artificial intelligence to interpret complex genomic data, resulting in actionable insights that resonate with health-conscious consumers and healthcare professionals alike.
 
The company is well-positioned in the market due to its user-friendly applications and the rising trend of personalized medicine. DnaNudge's focus on consumer engagement and empowerment through genetic insights strengthens its competitive advantage, making it a notable player in the genomic landscape.BioSymetrics operates within the AI in Genomics Market, specializing in AI-driven solutions for understanding complex biological data. This company focuses on combining clinical, genomic, and biometric data to develop predictive models that can enhance drug discovery processes and facilitate targeted therapeutic strategies.
 
BioSymetrics has established a unique data architecture that allows for the integration and analysis of multi-modal data, which is essential in the personalized medicine arena. The strength of BioSymetrics lies in its cutting-edge algorithms and analytical capabilities that streamline the translation of genomic data into clinical applications. The company’s commitment to innovation and a deep focus on machine learning techniques empower it to deliver valuable insights to researchers and healthcare providers, placing BioSymetrics as a competitive entity in the ever-growing AI genomics space.

## Recent News & Developments

- **Q2 2024: Illumina and NVIDIA Collaborate to Accelerate AI Genomics Analysis** Illumina announced a partnership with NVIDIA to integrate NVIDIA's AI computing platform into Illumina's genomics analysis workflows, aiming to speed up and scale genomic data interpretation for research and clinical applications.
- **Q2 2024: Fabric Genomics Raises $30 Million in Series C Funding to Advance AI-Driven Genomic Interpretation** Fabric Genomics secured $30 million in Series C funding to expand its AI-powered genomic interpretation platform, supporting clinical diagnostics and precision medicine initiatives.
- **Q2 2024: Tempus Announces Acquisition of AI Genomics Startup Pangea Biomed** Tempus, a leader in AI-driven precision medicine, acquired Pangea Biomed, an AI genomics startup, to enhance its oncology and rare disease genomics capabilities.
- **Q3 2024: Oxford Nanopore Technologies and Microsoft Partner to Develop AI Genomics Tools** Oxford Nanopore Technologies entered a strategic partnership with Microsoft to co-develop AI-powered tools for real-time genomic data analysis, targeting healthcare and research markets.
- **Q3 2024: Grail Launches New AI-Enabled Genomic Cancer Screening Test** Grail announced the commercial launch of a new AI-enabled genomic test designed to detect multiple types of cancer from a single blood draw, leveraging advanced machine learning algorithms.
- **Q3 2024: SOPHiA GENETICS Expands AI Genomics Platform to Asia Through Partnership with BGI** SOPHiA GENETICS formed a partnership with BGI to expand its AI-powered genomics analytics platform into Asian markets, aiming to accelerate adoption in clinical and research settings.
- **Q4 2024: Deep Genomics Raises $100 Million Series D to Advance AI Drug Discovery Platform** Deep Genomics closed a $100 million Series D funding round to further develop its AI-driven platform for genomic drug discovery and expand its therapeutic pipeline.
- **Q4 2024: PathAI Receives FDA Clearance for AI Genomics Companion Diagnostic** PathAI announced FDA clearance for its AI-powered genomics companion diagnostic, enabling more precise patient selection for targeted cancer therapies.
- **Q1 2025: Celsius Therapeutics Raises $75 Million Series B to Scale AI Genomics Platform** Celsius Therapeutics raised $75 million in Series B funding to scale its AI-driven genomics platform focused on autoimmune disease and oncology research.
- **Q1 2025: DNAnexus Launches AI-Enhanced Genomics Data Platform for Biopharma** DNAnexus launched a new AI-enhanced genomics data platform designed to support biopharmaceutical companies in large-scale genomic data analysis and drug development.
- **Q2 2025: 23andMe Appoints New Chief AI Officer to Lead Genomics Innovation** 23andMe appointed a Chief AI Officer to spearhead the company's efforts in integrating artificial intelligence into its consumer genomics and health research initiatives.
- **Q2 2025: Helix Opens New AI Genomics Research Facility in San Diego** Helix announced the opening of a new research facility in San Diego dedicated to advancing AI-powered genomics research and accelerating the development of precision medicine solutions.

## Report Scope

| MARKET SIZE 2024 | 14.22(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 16.76(USD Billion) |
| MARKET SIZE 2035 | 86.85(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.88% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), GRAIL (US), Freenome (US), Zymergen (US), BenevolentAI (GB), Genomatix (DE) |
| Segments Covered | Applications, Technology, Deployment Type, End Users, Solution Type, Regional - Forecast to 2035 |
| Key Market Opportunities | Integration of advanced machine learning algorithms enhances genomic data analysis and personalized medicine. |
| Key Market Dynamics | Rising integration of artificial intelligence in genomics enhances precision medicine and accelerates drug discovery processes. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of AI in Genomics by 2035?**
A: The AI in Genomics market is projected to reach a valuation of 86.85 USD Billion by 2035.

**Q: What was the market valuation of AI in Genomics in 2024?**
A: In 2024, the AI in Genomics market was valued at 14.22 USD Billion.

**Q: What is the expected CAGR for the AI in Genomics market from 2025 to 2035?**
A: The expected CAGR for the AI in Genomics market during the forecast period 2025 - 2035 is 17.88%.

**Q: Which application segment is projected to have the highest valuation by 2035?**
A: The Genomic Data Analysis segment is projected to reach 21.12 USD Billion by 2035.

**Q: What are the leading technologies driving the AI in Genomics market?**
A: Machine Learning and Deep Learning are leading technologies, with projected valuations of 30.0 USD Billion and 25.0 USD Billion, respectively, by 2035.

**Q: How does the deployment type of AI in Genomics market segment compare?**
A: Cloud-Based deployment is expected to dominate with a projected valuation of 48.0 USD Billion by 2035, compared to 38.85 USD Billion for On-Premises.

**Q: Which end-user segment is anticipated to grow the most by 2035?**
A: Pharmaceutical Companies are anticipated to grow significantly, reaching a valuation of 30.0 USD Billion by 2035.

**Q: What is the projected growth for software solutions in the AI in Genomics market?**
A: Software solutions are projected to reach 30.0 USD Billion by 2035, indicating robust growth.

**Q: Who are the key players in the AI in Genomics market?**
A: Key players include Illumina, Thermo Fisher Scientific, Bristol-Myers Squibb, and Regeneron Pharmaceuticals.

**Q: What is the projected valuation for the Diagnostics application segment by 2035?**
A: The Diagnostics application segment is projected to reach a valuation of 17.65 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/ai-genomics-market-31278*